Medytox said it reported strong business performance in the second quarter thanks to the ramp-up of production at its third manufacturing plant in Osong, North Chungcheong Province.

The company marked sales and operating profit of 65 billion won ($47.6 million) and 14.3 billion won in the second quarter, up 26 percent and 50 percent a year ago. It also posted a net profit of 11.3 billion won, a 33 percent increase.

Medytox attributed the robust growth to the ramp-up of production at its third manufacturing plant equipped with large-scale production lines focused on meeting the increasing demand for exports.

The company explained that its strategic approach of diversifying its product lineup and targeting specific segments also played a role in driving sales growth.

Its sales of toxin products marked significant increases, with domestic sales rising by 21 percent and overseas sales by 24 percent compared to the same period last year.

The company's filler products also experienced growth of 19 percent in the domestic market and 29 percent in international markets.

More specifically, the company recorded impressive sales growth in areas that it regards as key markets -- Asia (26 percent), Europe (167 percent), and the Middle East (33 percent).

In addition to its core products, Medytox's derma-cosmetic brand, Neuraderm, contributed to its growth.

The brand’s expansion, including the launch of new products and increased visibility through platforms like Japan's Rakuten and Olive Young’s online mall, has strengthened its market presence.

"Our focus on revenue growth in the first half of the year has resulted in achieving record sales in the second quarter,” a Medytox official said. “As we continue to create a sustainable growth environment, we expect profitability to recover rapidly as litigation-related expenses decrease."

The official added that Medytox is diligently preparing several large-scale projects that will further enhance the company's value.